Physician profile
Wainwright A Jaggernauth
NPI 1689670580
$863.85
in general payments reported to CMS, 2019-2025
17 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $12.41 · 2021: $11.04 · 2023: $43.84 · 2024: $266 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $174.52 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $145.64 | 2024-2025 | Libtayo, Dupixent |
| Pinnacle Biologics, INC | $124.56 | 2024 | Photofrin |
| Covidien LP | $74.70 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $68.23 | 2019-2025 | |
| Focal Therapeutics, INC. | $48.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.42 | 2025 | |
| Merck Sharp & Dohme LLC | $30.47 | 2025 | Keytruda, Keytruda Qlex |
| Bayer Healthcare Pharmaceuticals INC. | $25.18 | 2025 | |
| Astellas Pharma Global Development | $24.25 | 2023 | Padcev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.80 | 2019 | |
| Telix Pharmaceuticals | $19.59 | 2023 | Illuccix |
| Exelixis INC. | $14.62 | 2019 | |
| Astellas Pharma US INC | $14.32 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $13.35 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Varian Medical Systems, INC. | $12.41 | 2020 | |
| Elekta, INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wainwright Jaggernauth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.